Wellbutrin XL Generic Needs Longer Study To Assess Switch Issues, Biovail Asserts
This article was originally published in The Pink Sheet Daily
Executive Summary
Bioequivalencey isn't the issue, Biovail says in response to proposed Teva study, arguing a much larger and differently designed trial should be conducted to investigate clinical differences between the generic and brand.